FY2029 Earnings Forecast for uniQure Issued By HC Wainwright

uniQure N.V. (NASDAQ:QURE) – HC Wainwright increased their FY2029 EPS estimates for shares of uniQure in a report issued on Monday, October 6th. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will earn $20.48 per share for the year, up from their previous forecast of $20.36. HC Wainwright currently has a “Buy” rating and a $110.00 target price on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.20. The firm had revenue of $5.26 million during the quarter, compared to analysts’ expectations of $5.00 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%.

A number of other analysts also recently commented on QURE. Weiss Ratings restated a “sell (d-)” rating on shares of uniQure in a research note on Saturday, September 27th. Mizuho boosted their price target on uniQure from $30.00 to $60.00 and gave the company an “outperform” rating in a report on Thursday, September 25th. Chardan Capital raised their price objective on shares of uniQure from $35.00 to $76.00 and gave the stock a “buy” rating in a research note on Thursday, September 25th. Stifel Nicolaus boosted their target price on shares of uniQure from $30.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Finally, UBS Group set a $95.00 price target on shares of uniQure in a report on Thursday, September 25th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, uniQure currently has an average rating of “Moderate Buy” and a consensus target price of $71.75.

uniQure Price Performance

Shares of QURE opened at $52.91 on Tuesday. The business’s 50-day moving average is $22.35 and its two-hundred day moving average is $16.67. The company has a market capitalization of $2.90 billion, a P/E ratio of -13.50 and a beta of 0.56. The company has a debt-to-equity ratio of 1.53, a quick ratio of 9.98 and a current ratio of 9.98. uniQure has a fifty-two week low of $5.03 and a fifty-two week high of $60.70.

Institutional Investors Weigh In On uniQure

Several large investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC raised its holdings in shares of uniQure by 358.0% during the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after acquiring an additional 5,538 shares during the last quarter. Mraz Amerine & Associates Inc. purchased a new stake in shares of uniQure during the first quarter worth approximately $106,000. KLP Kapitalforvaltning AS acquired a new position in uniQure in the 2nd quarter valued at $117,000. Teacher Retirement System of Texas purchased a new position in uniQure in the 2nd quarter valued at $151,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in uniQure in the 1st quarter valued at $152,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Matthew C. Kapusta sold 226,316 shares of uniQure stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $41.46, for a total value of $9,383,061.36. Following the sale, the chief executive officer owned 651,454 shares in the company, valued at $27,009,282.84. This trade represents a 25.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Christian Klemt sold 15,000 shares of the business’s stock in a transaction dated Friday, September 26th. The stock was sold at an average price of $55.00, for a total transaction of $825,000.00. Following the sale, the chief financial officer directly owned 217,730 shares of the company’s stock, valued at $11,975,150. This represents a 6.45% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 244,316 shares of company stock worth $10,328,181 in the last three months. 4.79% of the stock is owned by corporate insiders.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.